Table 2: Characteristics of clinical trials of acupressure therapy for primary dysmenorrhea.

Study IDLocationN * Mean age (SD)*Intervention Control Outcome

Bazarganipour et al. 2010 [15]Iran88/8420.01 (1.01)/19.92 (0.87)AP, Taichong, 2 minutes, continued for 20 minutesPlacebo pointAndersch and Milsom scale

H. M. Chen and C. H. Chen 2004 [16]Taiwan, China 35/3418.06 (1.28)/17.54 (1.54)AP, once a day for bleeding (4–6 weeks); SanyinjiaoWaiting list controlMDQ, SF-MPQ, VAS for pain, VAS for anxiety

H. M. Chen and C. H. Chen 2010 [17]Taiwan, China30/33/36/3516.75 (1.36)/16.83 (1.79)/16.88 (2.09)/16.77 (1.19)AP, Zusanli, Hegu, Sanyinjiao, for 20 minutes Rest, for 20 minutesMDQ, SF-MPQ, VAS for pain, VAS for anxiety

Kashefi et al. 2010 [18]Iran40/41NAAP, SanyinjiaoPlacebo APVAS, SF-MPQ

Mirbagher-Ajorpaz et al. 2011 [19]Iran15/1522 (1.6)/22 (2.64)AP, Sanyinjiao Placebo AP, Sanyinjiao VAS

Pouresmail and Ibrahimzadeh 2002 [20]Iran72/72/72NAAP, once per 2 days from 24 h prior to bleeding (3 months); Hegu, Daheng, Zusanli, Sanyinjiao, Taichong(a) Ibuprofen 9 tablets for 3 days; (b) Sham AP (nonacupoints)Andersch and Milsom scale, VAS

Taylor et al. 2002 [21]USA31/2730.7 (6.2)/32.7 (5.5) AP plus Ibuprofen, device placed from day one of bleeding for 3 days (two menstrual cycles) IbuprofenWorst menstrual pain, menstrual symptom intensity, pain medication consumption

Wong et al. 2010 [22]Hong Kong, China19/2122 (0.082)/21.57 (0.746)SP6 acupressureRest VAS, SF-MPQ, SF-MDQ

Appendix. *Intervention group/control group; AP: acupressure; VAS: visual analogue scale; SF-MDQ: Short-Form Menstrual Distress Questionnaire; SF-MPQ: Short-Form McGill Pain Questionnaire; NA: not available.